Loading organizations...
§ Private Profile · Tempe, AZ, USA
Nectero Medical is a technology company.
Nectero Medical develops the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, a novel therapy designed to stabilize the growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). This system utilizes an endovascular approach to deliver a proprietary mixture directly to the aneurysm site, aiming to minimize further arterial wall degradation and strengthen the aortic tissue, thereby potentially averting or significantly delaying the need for invasive surgical intervention.
The company originated in 2017 as a continuation of translational work previously undertaken by Vatrix Medical, addressing a significant unmet need in vascular health. This strategic restart enabled the advancement of a new treatment paradigm for aneurysmal disease, focusing on conditions that fall outside the current criteria for surgical repair but still pose substantial risk to patients.
Nectero Medical targets patients with small to mid-sized AAAs who are currently under active surveillance without a definitive treatment option. Its vision is to transform lives by revolutionizing the management of aneurysmal disease, offering a preventative therapy that allows many patients to avoid the complexities and risks associated with major open or endovascular aneurysm repair.
Nectero Medical has raised $115.5M across 2 funding rounds.
Nectero Medical has raised $115.5M in total across 2 funding rounds.
Nectero Medical has raised $115.5M across 2 funding rounds. Most recently, it raised $96.0M Series D in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $96M Series D | Zack Scott | Alumni Ventures, Amity Ventures, Ehukai Investments, Norwest Venture Partners, Origin Ventures, S3 Ventures, Trucks Venture Capital, Aphelion Capital, Alan Davis, Boston Scientific, Cadence Healthcare Ventures | Announced |
| Sep 10, 2021 | $19.5M Series C | Boston Scientific | — | Announced |
Nectero Medical has raised $115.5M in total across 2 funding rounds.
Nectero Medical's investors include Zack Scott, Alumni Ventures, Amity Ventures, Ehukai Investments, Norwest Venture Partners, Origin Ventures, S3 Ventures, Trucks Venture Capital, Aphelion Capital, Alan Davis, Boston Scientific, Cadence Healthcare Ventures.
Nectero Medical is a clinical-stage biotechnology and medical technology company developing the Nectero Endovascular Aneurysm Stabilization Treatment (EAST®) System, a minimally invasive, single-dose endovascular therapy for small to medium-sized infrarenal abdominal aortic aneurysms (AAAs) measuring 3.5–5.0 cm in diameter[1][2][4]. The system uses a dual-balloon delivery catheter to locally apply pentagalloylglucose (PGG), which binds to elastin and collagen in the aneurysmal wall to strengthen it, slow growth, and reduce rupture risk without leaving a permanent implant[1][2][4]. It targets patients under active surveillance who are not yet surgical candidates, addressing a critical unmet need where over 15,000 U.S. patients die annually from ruptured AAAs[3]. The company, based in Tempe, Arizona, has raised $115.5M in funding, including a $96M Series D in 2024, and is enrolling in the pivotal Phase II/III stAAAble trial after receiving FDA Fast Track and Breakthrough Therapy designations in 2023[1][2][4].
Growth momentum is strong, with awards like the 2024 AZBio Fast Lane Award, ongoing trial initiation, and plans for FDA New Drug Application submission[1][4].
Founded in 2017 in Tempe, Arizona, Nectero Medical emerged to tackle the lack of non-surgical options for early to mid-sized AAAs, where patients face lifelong surveillance or high-risk invasive procedures[1][3]. The idea stemmed from the need for a simple, catheter-based treatment to stabilize aneurysms before rupture, led by a multidisciplinary team with deep expertise in vascular interventions and device development[1][5]. Key early milestones include positive Phase 1 safety study results, a $19.5M Series C financing in an earlier round led by Boston Scientific, and FDA Breakthrough Therapy designation in 2023, paving the way for the stAAAble trial launch in 2024[1][3][4]. Leadership under President and CEO Jack Springer, alongside advisers like Venkatesh Ramaiah, MD, has driven progress, with recent board additions like Zack Scott, MD, and Alan Davis, MD, from Series D investors[4][5].
Nectero rides the wave of advances in endovascular therapies and tissue stabilization biotech, targeting the growing AAA market amid an aging population and rising aneurysm prevalence[3]. Timing is ideal post-FDA designations and trial initiation, aligning with demand for less invasive alternatives to open surgery or EVAR, which carry long-term risks[1][3][4]. Favorable market forces include investor enthusiasm (e.g., $96M Series D) and recognition like AZBio awards, positioning Nectero to influence vascular medtech by enabling earlier intervention and reducing rupture-related deaths[1][4]. It contributes to the ecosystem by partnering with firms like Boston Scientific and advancing clinical data that could reshape AAA management standards[3][4].
Nectero is poised for commercialization post-stAAAble trial data, with NDA submission targeted soon after completion, potentially transforming AAA care by 2026–2027[4]. Trends like biotech-regulatory fast-tracking and endovascular innovation will propel it, especially if trial success validates stabilization claims. Its influence may expand to other aneurysmal diseases, amplifying impact in a high-unmet-need vascular space—echoing its origins as a pioneer against aneurysm progression[1][3].